- Home
- GAME vs SCLX Comparison
GAME vs SCLX Comparison
Compare GAME & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- SCLX
- Stock Information
- Founded
- GAME 2011
- SCLX 2011
- Country
- GAME United States
- SCLX United States
- Employees
- GAME N/A
- SCLX N/A
- Industry
- GAME
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- GAME
- SCLX Health Care
- Exchange
- GAME Nasdaq
- SCLX Nasdaq
- Market Cap
- GAME 27.2M
- SCLX 28.4M
- IPO Year
- GAME 2009
- SCLX N/A
- Fundamental
- Price
- GAME $0.85
- SCLX $6.31
- Analyst Decision
- GAME Strong Buy
- SCLX Strong Buy
- Analyst Count
- GAME 3
- SCLX 4
- Target Price
- GAME $3.67
- SCLX $396.67
- AVG Volume (30 Days)
- GAME 433.5K
- SCLX 143.5K
- Earning Date
- GAME 05-15-2025
- SCLX 05-14-2025
- Dividend Yield
- GAME N/A
- SCLX N/A
- EPS Growth
- GAME N/A
- SCLX N/A
- EPS
- GAME N/A
- SCLX N/A
- Revenue
- GAME $99,579,536.00
- SCLX $50,710,000.00
- Revenue This Year
- GAME $6.08
- SCLX $169.34
- Revenue Next Year
- GAME $21.94
- SCLX $86.92
- P/E Ratio
- GAME N/A
- SCLX N/A
- Revenue Growth
- GAME 77.06
- SCLX 7.79
- 52 Week Low
- GAME $0.50
- SCLX $3.60
- 52 Week High
- GAME $1.43
- SCLX $80.50
- Technical
- Relative Strength Index (RSI)
- GAME 58.35
- SCLX 57.66
- Support Level
- GAME $0.86
- SCLX $4.76
- Resistance Level
- GAME $0.92
- SCLX $7.52
- Average True Range (ATR)
- GAME 0.07
- SCLX 0.71
- MACD
- GAME 0.01
- SCLX 0.31
- Stochastic Oscillator
- GAME 50.74
- SCLX 64.83
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Its next generation media, entertainment, and technology help creators and maximize its brand partners return on investment. Its purpose-built platform, provide marketing and creative services, offer data and analytics solutions, and amplify awareness through FaZe Clan.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.